Article

Rapid PSA rise may point to high risk of prostate cancer death

Men whose PSA level increases by more than 2.0 ng/mL during the year prior to a prostate cancer diagnosis may have a relatively high risk of future cancer death even if they undergo radical prostatectomy, according to a recent report in the New England Journal of Medicine (2004; 351:125-35).

Related Videos
Margaret Knoedler, MD, on robot-assisted mini-PCNL with the Monarch Platform
Margaret Knoedler, MD, on robot-assisted mini-PCNL with the Monarch Platform
Khurshid Ghani, MBChB, MS, FRCS, on current barriers to stent omission
Khurshid Ghani, MBChB, MS, FRCS, on current barriers to stent omission
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Expert discusses differentiating prostate cancer from age-related issues
Howard Goldman, MD, discusses development of the Glean Urodynamics System
Howard Goldman, MD, discusses development of the Glean Urodynamics System
1 expert is featured in this series.
Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
1 expert is featured in this series.
A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
3 experts are featured in this series.
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
1 expert is featured in this series.
Remaining unmet needs in diverse populations with mHSPC
Related Content
Two business partnership coworkers discussing a financial planning graph and company during a budget meeting in office room. | Image Credit: © wutzkoh - stock.adobe.com
June 18th 2025

Money Matters: A financial guide to approaching retirement

Ronald J. Paprocki, JD, CFP, CHBC
"Estimate how much you will need to spend each year during various stages of retirement," advises Ronald J. Paprocki, JD, CFP, CHBC.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
June 17th 2025

FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

Hannah Clarke
Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Medicine doctor hand working with modern digital tablet computer interface as medical network concept | Image Credit: © NINENII - stock.adobe.com
June 16th 2025

CPT 49186 vs 38780: Coding retroperitoneal mass excision

Jonathan Rubenstein, MD Mark Painter
"We believe the confusion comes from the typical lexicon surgeons use when performing surgeries, rather than the actual code descriptor and the procedure performed," write Jonathan Rubenstein, MD, and Mark Painter.
From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
June 16th 2025

From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance

Anne K. Schuckman, MD Hannah Clarke
Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
© 2025 MJH Life Sciences

All rights reserved.